{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=NaCl-saline+placebo&page=13",
    "query": {
      "intervention": "NaCl-saline placebo",
      "page": 13
    },
    "page_size": 10
  },
  "pagination": {
    "page": 13,
    "page_size": 10,
    "total_count": 1335,
    "total_pages": 134,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=NaCl-saline+placebo&page=14&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=NaCl-saline+placebo&page=12&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T19:29:34.520Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04897412",
      "title": "A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Subcutaneous Fat"
      ],
      "interventions": [
        {
          "name": "CBL-514 Injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Caliway Biopharmaceuticals Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 75,
      "start_date": "2022-02-14",
      "completion_date": "2023-03-22",
      "has_results": false,
      "last_update_posted_date": "2023-04-24",
      "last_synced_at": "2026-10-14T19:29:34.520Z",
      "location_count": 4,
      "location_summary": "Chicago, Illinois • Omaha, Nebraska • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04897412"
    },
    {
      "nct_id": "NCT04384523",
      "title": "A Study of OsrHSA in Adult Healthy Male and Female Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ascites Hepatic"
      ],
      "interventions": [
        {
          "name": "OsrHSA 20 mg/kg IV",
          "type": "DRUG"
        },
        {
          "name": "OsrHSA 40 mg/kg IV",
          "type": "DRUG"
        },
        {
          "name": "OsrHSA 80 mg/kg IV",
          "type": "DRUG"
        },
        {
          "name": "OsrHSA 140 mg/kg IV",
          "type": "DRUG"
        },
        {
          "name": "OsrHSA 200 mg/kg IV",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Healthgen Biotechnology Corp.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 41,
      "start_date": "2019-11-04",
      "completion_date": "2020-07-13",
      "has_results": true,
      "last_update_posted_date": "2021-06-01",
      "last_synced_at": "2026-10-14T19:29:34.520Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04384523"
    },
    {
      "nct_id": "NCT01693653",
      "title": "Tocilizumab for the Treatment of Behcet's Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Behcet Syndrome"
      ],
      "interventions": [
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2012-09",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2019-02-15",
      "last_synced_at": "2026-10-14T19:29:34.520Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01693653"
    },
    {
      "nct_id": "NCT00005777",
      "title": "Minimal Breathing Support and Early Steroids to Prevent Chronic Lung Disease in Extremely Premature Infants (SAVE)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bronchopulmonary Dysplasia",
        "Respiratory Distress Syndrome",
        "Infant, Newborn",
        "Infant, Low Birth Weight",
        "Infant, Small for Gestational Age",
        "Infant, Premature"
      ],
      "interventions": [
        {
          "name": "Minimal mechanical ventilation management",
          "type": "PROCEDURE"
        },
        {
          "name": "Routine mechanical ventilation management",
          "type": "PROCEDURE"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "NICHD Neonatal Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Minutes",
        "maximum_age": "10 Days",
        "sex": "ALL",
        "summary": "5 Minutes to 10 Days"
      },
      "enrollment_count": 220,
      "start_date": "1998-02",
      "completion_date": "2002-09",
      "has_results": false,
      "last_update_posted_date": "2015-06-08",
      "last_synced_at": "2026-10-14T19:29:34.520Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005777"
    },
    {
      "nct_id": "NCT00195312",
      "title": "Study Evaluating Vaccine in Adults With HIV",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "HIV-1 gag DNA (formulated with bupivacaine)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IL-15 DNA (formulated with bupivacaine)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IL-12 DNA (formulated with bupivacaine)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sodium chloride injection USP (0.9%)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 91,
      "start_date": "2005-08",
      "completion_date": "2007-08",
      "has_results": false,
      "last_update_posted_date": "2007-12-05",
      "last_synced_at": "2026-10-14T19:29:34.520Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Denver, Colorado • Orlando, Florida + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00195312"
    },
    {
      "nct_id": "NCT02546570",
      "title": "Oxytocin and Affect Processing in Posttraumatic Stress Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Posttraumatic Stress Disorder (PTSD)"
      ],
      "interventions": [
        {
          "name": "Oxytocin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 11,
      "start_date": "2015-08",
      "completion_date": "2016-08",
      "has_results": true,
      "last_update_posted_date": "2020-04-08",
      "last_synced_at": "2026-10-14T19:29:34.520Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02546570"
    },
    {
      "nct_id": "NCT01545570",
      "title": "A Study to Determine the Safety, Tolerability, and Effects of GSK2374697 in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "GSK2376497",
          "type": "DRUG"
        },
        {
          "name": "0.9% sodium chloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 82,
      "start_date": "2011-11-07",
      "completion_date": "2012-12-23",
      "has_results": false,
      "last_update_posted_date": "2017-07-25",
      "last_synced_at": "2026-10-14T19:29:34.520Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01545570"
    },
    {
      "nct_id": "NCT02237053",
      "title": "Effects of Glucagon Administration on Energy Expenditure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hyperglucagonemia",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Glucagon",
          "type": "DRUG"
        },
        {
          "name": "Octreotide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Insulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "AdventHealth Translational Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "18 Years to 50 Years · Male only"
      },
      "enrollment_count": 6,
      "start_date": "2014-09",
      "completion_date": "2016-06",
      "has_results": false,
      "last_update_posted_date": "2018-04-26",
      "last_synced_at": "2026-10-14T19:29:34.520Z",
      "location_count": 1,
      "location_summary": "Orlando, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02237053"
    },
    {
      "nct_id": "NCT01594437",
      "title": "Safety Study of Human Anti-Cytomegalovirus Monoclonal Antibody",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cytomegalovirus Infections"
      ],
      "interventions": [
        {
          "name": "TCN-202",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Theraclone Sciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 48,
      "start_date": "2012-05",
      "completion_date": "2013-03",
      "has_results": false,
      "last_update_posted_date": "2014-03-21",
      "last_synced_at": "2026-10-14T19:29:34.520Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01594437"
    },
    {
      "nct_id": "NCT03984812",
      "title": "Evaluation of the Safety, Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "GSK3732394",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 24,
      "start_date": "2019-06-17",
      "completion_date": "2020-03-23",
      "has_results": true,
      "last_update_posted_date": "2021-10-25",
      "last_synced_at": "2026-10-14T19:29:34.520Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03984812"
    }
  ]
}